An update from Prime Medicine

  • New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function
  • New preliminary safety analyses demonstrated no detected off-target activity in Prime Edited Wilson’s disease cells
  • New data leveraging PASSIGE technology demonstrated ability to integrate kilobase-sized DNA in human T cells
  • Additional LNP and AAV delivery data demonstrated efficient in vivo delivery of Prime Editing to various target tissues in rodents
  • Multiple catalysts expected in 2023, including first development candidate nomination in 1Q and additional in vivo data in 2H
  • Strong corporate position, with robust intellectual property position and cash to fund operations into 2025